ASH 2020 snapshot: efficacy data in hot emerging areas
A roundup of clinical trial readouts for CD47 blockers, allogeneic CAR T cells and sickle cell disease
A roundup of clinical trial readouts for CD47 blockers, allogeneic CAR T cells and therapies addressing the root cause of sickle cell disease.
This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease.
Abstracts released ahead of the virtual 2020 American Society of Hematology (ASH) meeting, to be held Dec. 5-8, show positive early signals for all three areas.
In some presentations, companies that had already amassed clinical data for their candidates have begun spotlighting the indications, patient subsets and manufacturing processes they plan to advance to the next stage of clinical development or to a regulatory filing. Other abstracts feature promising early signals for newer agents.
Abstracts from the Society for Immunotherapy of Cancer (SITC) meeting, taking place Nov. 9-14, provide additional glimpses